

Klarissa D Jackson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6887892/publications.pdf>

Version: 2024-02-01

17
papers

298
citations

1163117

8
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

341
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib. <i>Chemical Research in Toxicology</i> , 2018, 31, 570-584.	3.3	62
2	Providing a New Aniline Bioisostere through the Photochemical Production of 1-Aminonorbornanes. <i>CheM</i> , 2019, 5, 215-226.	11.7	58
3	Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1584-1597.	3.3	36
4	Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2367.	4.1	36
5	Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol. <i>Drug Metabolism and Disposition</i> , 2021, 49, 882-891.	3.3	30
6	Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1257-1269.	3.3	19
7	HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase II α and II β . <i>Chemical Research in Toxicology</i> , 2018, 31, 137-144.	3.3	13
8	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. <i>Circulation Research</i> , 2021, 128, 1973-1987.	4.5	10
9	Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib. <i>Drug Metabolism and Disposition</i> , 2021, 49, 233-244.	3.3	9
10	Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation. <i>Chemical Research in Toxicology</i> , 2022, 35, 792-806.	3.3	8
11	Novel advances in biotransformation and bioactivation research—2019 year in review. <i>Drug Metabolism Reviews</i> , 2020, 52, 333-365.	3.6	5
12	Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. <i>Xenobiotica</i> , 2020, 50, 132-145.	1.1	4
13	Novel advances in biotransformation and bioactivation research — 2020 year in review. <i>Drug Metabolism Reviews</i> , 2021, 53, 384-433.	3.6	4
14	Biotransformation novel advances — 2021 year in review. <i>Drug Metabolism Reviews</i> , 2022, 54, 207-245.	3.6	3
15	Case Study 11: Considerations for Enzyme Mapping Experiments—Interaction Between the Aldehyde Inhibitor Hydralazine and Glutathione. <i>Methods in Molecular Biology</i> , 2021, 2342, 809-823.	0.9	1
16	Interindividual Variation in Sunitinib Metabolism in Primary Human Hepatocytes. <i>FASEB Journal</i> , 2019, 33, 820.5.	0.5	0
17	Investigating the CYP450-Catalyzed Metabolism of Cannabidiol and Its Implications for Drug Safety. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0